Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at Stifel Nicolaus

Analysts at Stifel Nicolaus assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 78.41% from the company’s previous close.

Several other brokerages have also recently commented on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Mizuho increased their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. HC Wainwright increased their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Guggenheim began coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.50.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $33.63 on Tuesday. The company’s 50-day moving average price is $41.32 and its two-hundred day moving average price is $30.28. Enliven Therapeutics has a one year low of $14.78 and a one year high of $48.53. The stock has a market capitalization of $2.05 billion, a PE ratio of -20.14 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, analysts anticipate that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new stake in Enliven Therapeutics in the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets boosted its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC bought a new stake in Enliven Therapeutics in the 4th quarter valued at about $83,000. Finally, Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.